Assay News and Research

RSS

Discovery may accelerate development of new drugs to treat Huntington's disease

By identifying in spinal fluid how the characteristic mutant proteins of Huntington's disease spread from cell to cell, UC Irvine scientists and colleagues have created a new method to quickly and accurately track the presence and proliferation of these neuron-damaging compounds -- a discovery that may accelerate the development of new drugs to treat this incurable disease.

24 Jun 2015

Roche unveils series of new diagnostic technologies at EuroMedLab

Today at the 21st annual meeting of the IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicines in Paris, France, Roche unveiled a series of new diagnostic technologies.

23 Jun 2015

Ortho Clinical Diagnostics announces FDA approval of VITROS Chemistry Products HbA1c Reagent Kit for diagnosis of diabetes

Ortho Clinical Diagnostics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the VITROS Chemistry Products HbA1c Reagent Kit to be used on the VITROS 5600 Integrated System, VITROS 4600 Chemistry System, and the VITROS 5,1 FS Chemistry System. The test can be used for the quantitative determination of percent glycated hemoglobin A1c (DCCT/NGSP) and mmol/mol hemoglobin A1c (IFCC) in human whole blood.

From Ortho-Clinical Diagnostics, Inc. 22 Jun 2015

ImmunoCellular, Pure MHC partner to develop new assay for ICT-107 phase 3 registrational clinical program

ImmunoCellular Therapeutics, Ltd. announced an agreement with Pure MHC, an Emergent Technologies portfolio company, for development of a novel assay for quality control that will be an important component of ImmunoCellular's ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015.

22 Jun 2015

TSRI scientists devise powerful set of chemical methods to explore protein biology

Scientists at The Scripps Research Institute (TSRI) have devised a powerful set of chemical methods for exploring the biology of proteins.

22 Jun 2015

Hitachi High-Technologies, QIAGEN form new strategic partnership to advance molecular testing

Hitachi High-Technologies Corporation and QIAGEN N.V. have entered into a long-term strategic collaboration involving initiatives to deliver important advances in molecular testing.

From QIAGEN Manchester Limited 18 Jun 2015

Highly efficient ChIP assay kit for FFPE samples

Chromatrap®, a business unit of Porvair Sciences, has introduced a new Formaldehyde Fixed Paraffin-Embedded (FFPE) ChIP Kit which overcomes the widely acknowledged shortfalls of the technique.

From Chromatrap® - Porvair Sciences Ltd 17 Jun 2015

Optimised ChIP protocols for qPCR and sequencing

Chromatrap®, a business unit of Porvair Sciences, has announced a new web page that brings together protocols developed using their proprietary solid state chromatin immunoprecipitation (ChIP) technology.

From Chromatrap® - Porvair Sciences Ltd 17 Jun 2015

CQDM, OCE grant $1.5M to speed up drug discovery and development in Quebec-Ontario Life Sciences Corridor

CQDM and Ontario Centres of Excellence will fund five highly innovative and unconventional game-changing research and development projects to accelerate drug discovery in the Quebec-Ontario Life Sciences Corridor. Partners are granting $1.5M to Quebec-based and, for the first time, Ontario-based researchers thanks to the partnership with OCE through CQDM's 2014 Explore Program, one of CQDM's flagship programs focusing on early concept validation of cutting-edge technologies that address the most crucial needs in drug discovery and development.

17 Jun 2015

Phase I study: Idarucizumab reverses anticoagulant effect of dabigatran in healthy volunteers

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that The Lancet published results from a phase I study investigating the effects of idarucizumab, an investigational agent, in reversing the anticoagulant effect of dabigatran in healthy volunteers. The data demonstrate that complete reversal was achieved following administration of idarucizumab.

17 Jun 2015

VENTANA ALK (D5F3) CDx Assay receives FDA approval

Ventana Medical Systems, Inc., a member of the Roche Group, today announced approval of the VENTANA ALK (D5F3) CDx Assay by the US Food and Drug Administration as a companion diagnostic to aid in the identification of patients for Pfizer's FDA approved targeted therapy, XALKORI (crizotinib).

15 Jun 2015

Study shows bacteriophages remain active against P. aeruginosa infection after nebulization

bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced new data demonstrating that bacteriophages remain active against Pseudomonas aeruginosa (P. aeruginosa) after nebulization.

15 Jun 2015

Clinical data of Trovagene's Precision Cancer Monitoring platform to be presented at two medical conferences

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer MonitoringSM platform will be presented at the 2015 Cancer Markers and Liquid Biopsies conference in San Diego, CA on June 11-12, and at the AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy in Salt Lake City, UT on June 13-16.

8 Jun 2015

New therapeutic target discovered for idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease for which as yet no causal therapy exists. It is, however, known that the lung interstitium - the connective tissue between the air sacs in the lower part of the lung - is affected.

8 Jun 2015

Profil Institute for Clinical Research forms strategic partnership with Gubra

Profil Institute for Clinical Research, an clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced today a strategic collaboration with Gubra ApS, a metabolic preclinical and drug discovery company, to combine expertise and resources to discover and translate into clinical research novel drug targets, compounds and biomarkers addressing metabolic disease.

4 Jun 2015

Novel strategy shows aptamer-based modular delivery of microRNA in endothelial, breast cancer cells

Researchers have shown that a novel delivery strategy can efficiently introduce a functional microRNA that has anti-cancer and angiogenic activities into two different types of cells--breast cancer cells to inhibit tumor growth and metastasis, and cells that line blood vessels to protect against atherosclerosis.

4 Jun 2015

Aushon BioSystems announces commercial release of Ultrasensitive Cira Assays

Aushon BioSystems, a leading provider of products and services for multiplex quantitative detection of protein biomarkers, today announced the commercial release of its Ultrasensitive Cira Assays capable of measuring concentrations of low abundance proteins down to the femtogram/mL level.

2 Jun 2015

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Astellas Pharma Inc. announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced androgen receptor (AR) positive, triple-negative breast cancer (TNBC) were presented during an oral abstracts session at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

2 Jun 2015

Pivotal Therapeutics reports net loss of $1.2 million for first quarter 2015

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended March 31, 2015.

2 Jun 2015

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Astellas Pharma Inc. today announced that preliminary data from a Phase 1/2 trial on the safety, tolerability and efficacy of ASP2215, a selective inhibitor of FLT3/AXL, in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) were presented during an oral abstract session at the American Society of Clinical Oncology's annual meeting in Chicago.

30 May 2015

Assay News and Research

Discovery may accelerate development of new drugs to treat Huntington's disease

Roche unveils series of new diagnostic technologies at EuroMedLab

Ortho Clinical Diagnostics announces FDA approval of VITROS Chemistry Products HbA1c Reagent Kit for diagnosis of diabetes

ImmunoCellular, Pure MHC partner to develop new assay for ICT-107 phase 3 registrational clinical program

TSRI scientists devise powerful set of chemical methods to explore protein biology

Hitachi High-Technologies, QIAGEN form new strategic partnership to advance molecular testing

Highly efficient ChIP assay kit for FFPE samples

Optimised ChIP protocols for qPCR and sequencing

CQDM, OCE grant $1.5M to speed up drug discovery and development in Quebec-Ontario Life Sciences Corridor

Phase I study: Idarucizumab reverses anticoagulant effect of dabigatran in healthy volunteers

VENTANA ALK (D5F3) CDx Assay receives FDA approval

Study shows bacteriophages remain active against P. aeruginosa infection after nebulization

Clinical data of Trovagene's Precision Cancer Monitoring platform to be presented at two medical conferences

New therapeutic target discovered for idiopathic pulmonary fibrosis

Profil Institute for Clinical Research forms strategic partnership with Gubra

Novel strategy shows aptamer-based modular delivery of microRNA in endothelial, breast cancer cells

Aushon BioSystems announces commercial release of Ultrasensitive Cira Assays

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Pivotal Therapeutics reports net loss of $1.2 million for first quarter 2015

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News